ClinicalTrials.gg
CompletedNCT01485848ESP2011-002Updated Jun 10, 2014

EP-100 Plus Paclitaxel Versus Paclitaxel Alone in Patients With Ovarian Cancer

A Phase 2 interventional study of EP-100 and Paclitaxel in Ovarian Cancer Recurrent, sponsored by Esperance Pharmaceuticals Inc. Completed at 15 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-06-10.

Sponsored by Esperance Pharmaceuticals Inc · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
49
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 155 studies testing paclitaxel in Ovarian Neoplasms — 13 open to participants now, 21 under way, 6 of them phase 3. Paclitaxel · Ovarian Neoplasms.

Enrollment
74th of 143
49 · median 50
Started
2012
with 6 others
Phase 2
83 of 155
8 open now
Registered
94th of 155
by date

Among the 155 studies testing paclitaxel in Ovarian Neoplasms, this one is the 74th largest by enrollment of the 143 interventional ones that give a count, is one of 7 that started in 2012, is one of 83 in phase 2, and was the 94th registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

13 of the 155 studies testing paclitaxel in Ovarian Neoplasms are open now, in 9 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About paclitaxel

Paclitaxel: first FDA approval 1992 (TAXOL), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 155 studies testing paclitaxel in Ovarian Neoplasms, or all of them as a file.
02

Study summary

Primary Objectives: o Run-in Phase: Determine a dose of EP-100 at which the initial benefit/risk of paclitaxel combined with EP-100 can be studied. o Randomized Phase: Compare the anti-tumor effects of EP-100 combined with weekly paclitaxel versus paclitaxel alone in patients with ovarian cancer. Secondary Objectives: o Randomized Phase: Quantify any significant changes in the safety profile of weekly paclitaxel alone compared to the doublet combination of paclitaxel with EP-100. o Determine an initial benefit/risk profile for this new drug combination.

Read the detailed description

Total duration of the study for each participant is 9 to 10 months, consisting of a 1 month screening period, a 6 to 7 months treatment period, and a 30 day follow-up. All patients with stable disease or who have achieved partial or complete response and for whom dosing has been safe and reasonably well-tolerated may continue additional treatment cycles on the same regimen. Any patient whose imaging assessment shows disease progression after receiving at least two cycles of single agent weekly paclitaxel on ARM 1 may then be offered treatment with the combination of EP-100 plus paclitaxel in the same dose regimen as ARM 2.

03

Conditions studied

  • Ovarian Cancer Recurrent

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients with confirmed epithelial ovarian carcinomas; these will include primary peritoneal and fallopian tube carcinomas. Patient's tumor shown to be positive for the LHRH-receptors by standardized immunocytochemistry performed at the study's central laboratory.
  • Reliable cancer treatment history documenting advanced disease in patients who have progressed during or recurred after treatment with a paclitaxel and/or platinum regimen for advanced disease.
  • Evaluable disease based on criteria of the Gynecologic Intergroup Response Evaluation Criteria in in Solid Tumors.
  • performance status >/= 70%.

Exclusion criteria

Exclusion criteria:

  • Significant cardiac disease.
  • Active, uncontrolled bacterial, viral, or fungal infections requiring systemic therapy.
  • Pregnant or nursing women.
  • Treatment with radiation therapy or therapy within 4 weeks prior to Day 1. Had received chemotherapy prior to study entry equivalent to 3 to 5 half-lives of that chemotherapy agent or 4 weeks prior to study entry (whichever is shorter) with resolution of any side effects from that previous therapy (6 weeks for nitrosoureas or Mitomycin C.)
  • Subjects with known central nervous system (CNS) , either previously treated or current.
  • Disease-free and off therapy for any other cancer within 5 years, except for adequately treated basal cell or squamous cell skin cancer or cervical intraepithelial neoplasia (CIN).
  • Had major surgery, other than diagnostic surgery, within 4 weeks prior to Day 1. o Had minor surgery (superficial incisions unlikely to obscure bleeding or infections) within 2 weeks prior to Day 1.
  • Potentially life-threatening disease (hypercalcemia, spinal cord compression) whose disease may progress acutely during therapy.
  • Unwilling or unable to comply with procedures required in this protocol.
  • Known infection with (HIV), , or .
  • Susceptibility to histamine release.
  • Chronic treatment with .
  • Baseline exceeding 450 msec (by Bazett's formula) and/or patients receiving class 1A or class III antiarrythmic agents.
  • Serious nonmalignant disease.
  • Subjects who are currently receiving any other investigational agent.
  • Inadequate renal and liver functions and bone marrow reserve.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
49 participants (actual)

Study arms

  • Active comparator
    Paclitaxel

    A single 1 hour intravenous infusion every week for 6 cycles (each cycle is 4 weeks)

    Drug: EP-100

  • Experimental
    Paclitaxel + EP-100

    Paclitaxel every week plus EP-100 twice weekly by 1 hour intravenous infusion for the first 3 weeks of each 4 week cycle for 6 cycles (each cycle is 4 weeks)

    Drug: Paclitaxel

Interventions

  • DrugEP-100

    Pharmaceutical form:Solution Route of administration: Intravenous

  • Pharmaceutical form:Solution Route of administration: Intravenous

06

What researchers measure

Primary outcomes

  1. Number of patients with dose limiting toxicities (DLTs) at different doses

    Time frame: Up to 30 weeks

  2. Overall Response Rate (ORR)

    Time frame: Up to 30 weeks

Secondary outcomes

  1. Time to Progression (TTP) - Time

    Time frame: Up to 18 months

  2. Progression-free Survival - Time

    Time frame: Up to 18 months

  3. Overall Survival (OS) - Time

    Time frame: Up to 18 months

  4. Duration of Response - Time

    Time frame: Up to 18 months

  5. Number of Participants with Adverse Events

    Time frame: Up to 18 months

07

Study locations

15 sites
  • Investigational Site Number 840001
    Greenbrae, California 94904-2011, United States
  • Investigational Site Number 840005
    San Francisco, California 94115, United States
  • Investigational Site Number 840007
    Louisville, Kentucky 40202, United States
  • Investigational Site Number 840010
    Covington, Louisiana 70433, United States
  • Investigational Site Number 840011
    Shreveport, Louisiana 71103, United States
  • Investigational Site Number 840503
    Bozeman, Montana 58715, United States
  • Investigational Site Number 840004
    Middletown, Ohio 45042, United States
  • Investigational Site Number 840008
    Portland, Oregon 97227-1191, United States
  • Investigational Site Number 840006
    Houston, Texas 77030, United States
  • Investigational Site Number 840603
    Kennewick, Washington 99336, United States
  • Investigational Site Number 840103
    Mount Vernon, Washington 98273, United States
  • Investigational Site Number 840403
    Seattle, Washington 98112, United States
  • Investigational Site Number 840003
    Seattle, Washington 98115, United States
  • Investigational Site Number 840303
    Tacoma, Washington 98415-0299, United States
  • Investigational Site Number 840203
    Wenatchee, Washington 98801, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2012, a primary completion of May 2014 and a completion of May 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2011
First posted
Dec 6, 2011
Start
Feb 2012
Primary completionActual
May 2014
CompletionActual
May 2014
Last update
Jun 10, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01485848
Lead sponsor
Esperance Pharmaceuticals Inc
Responsible party
Sponsor
First posted
Dec 6, 2011
Start date
Feb 2012
Primary completion
May 2014
Completion
May 2014
Last update
Jun 10, 2014

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Paclitaxel

Start the discussion